HYTN Innovations Partners with 4C Labs for UK Export
VANCOUVER, British Columbia — HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) is excited to announce its successful acquisition of initial orders and import permits from the UK's esteemed 4C Labs. This achievement represents an important milestone in their ongoing collaboration, allowing HYTN to initiate the exportation of premium cannabis-based pharmaceuticals to the UK. The first shipment, produced under strict Good Manufacturing Practices (GMP) standards, highlights the company's dedication to broadening its global footprint and delivering top-tier cannabis products to international markets.
CEO's Vision on Global Expansion
In a statement regarding this accomplishment, Elliot McKerr, the Chief Executive Officer of HYTN, expressed his enthusiasm, saying, “We are thrilled to take this next step with 4C Labs. This milestone signifies the strength of our partnership and marks our transition from a domestic market player to an international cannabis company.”
Registration and Compliance Achievements
HYTN's receipt of initial orders and importation permits necessitated the company's registration on the UK's National Drugs Control System (NDS), a pivotal step that has already been achieved. With this important registration, HYTN is now authorized to engage in transactions with UK firms that possess the necessary domestic controlled drug or domestic drug precursor licenses. This approval paves the way for HYTN to explore further opportunities in the UK market.
About HYTN Innovations Inc.
HYTN Innovations Inc. is committed to advancing the formulation, manufacturing, marketing, and sale of psychoactive and psychotropic products, including those derived from cannabis and psilocybin. The company is steadfast in its goal to become a leading provider of these innovative products across various federally regulated markets. To achieve this, HYTN strategically identifies and capitalizes on emerging market opportunities through its robust development platform.
Insight into 4C LABS Ltd.
4C LABS is a Canadian medical cannabis organization dedicated to fostering a vertically integrated, quality-driven framework for the sourcing and supply of premium medical cannabis products to the UK, EU, and other regulated international markets. The company prioritizes product launches in compliant markets while actively investing in the research and development of novel plant-based therapeutic formulations to enhance its product catalog.
Understanding Good Manufacturing Practices (GMP)
Good Manufacturing Practices (GMP) guidelines are essential for overseeing the manufacturing, testing, and quality assurance processes, ensuring that products are safe for human use. Many nations require adherence to GMP standards, tailoring their guidelines to meet local legislation. The importance of GMP cannot be overstated as it forms the bedrock of trust in the pharmaceutical industry.
Contact Information
For further inquiries or information, please contact:
Elliot McKerr
Chief Executive Officer
1.866.590.9289
HYTN Investor Relations:
1.866.590.9289
investments@hytn.life
Frequently Asked Questions
What did HYTN Innovations recently achieve?
HYTN Innovations received opening orders and import permits from the UK's 4C Labs, marking a significant step in their international expansion.
What does this partnership allow HYTN to do?
The partnership enables HYTN to export premium cannabis-based pharmaceuticals to the UK, expanding their global market reach.
What are Good Manufacturing Practices (GMP)?
GMP guidelines are regulations ensuring product quality and safety during manufacturing, crucial for the pharmaceutical and cannabis industries.
Who is the CEO of HYTN Innovations?
Elliot McKerr serves as the CEO of HYTN Innovations and has been vocal about the company's strategic international initiatives.
How can I contact HYTN Innovations?
Interested parties can contact Elliot McKerr at 1.866.590.9289 or reach out to HYTN Investor Relations via email at investments@hytn.life.
